Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Elizabeth Ng was appointed as Chief Executive Officer and Class III Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Chief Executive Officer and Class III Director
Exact text from the filing
Elizabeth Ng, MBA 66 Chief Executive Officer and Class III Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Chirinjeev Kathuria was appointed as Founder, Executive Chairman, Class III Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Founder, Executive Chairman, Class III Director
Exact text from the filing
Dr. Chirinjeev Kathuria, M.D. 58 Founder, Executive Chairman, Class III Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Behr was appointed as Executive Vice President and Head of External Innovation and Academic Partnerships at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Executive Vice President and Head of External Innovation and Academic Partnerships
Exact text from the filing
Daniel Behr, MBA 64 Executive Vice President and Head of External Innovation and Academic Partnerships
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William Owens was appointed as Class I Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
William Owens (1)(3) 72 Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Inderjote Kathuria was appointed as Chief Strategy Officer at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Chief Strategy Officer
Exact text from the filing
Inderjote Kathuria, M.D. 56 Chief Strategy Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Martin D. Angle was appointed as Class II Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Martin D. Angle (1)(2) 72 Class II Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jonathan Kurtis was appointed as Class I Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
Jonathan Kurtis, M.D., Ph.D. 55 Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Sweeney was appointed as Chief Accounting Officer at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Chief Accounting Officer
Exact text from the filing
Robert Sweeney 57 Chief Accounting Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michelle Berrey was appointed as Class I Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
Michelle Berrey, M.D., MPH (1)(2)(3) 56 Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Suren Ajjarapu departed as Chairman and Chief Executive Officer at Ocean Biomedical, Inc..
- Role
- Chairman and Chief Executive Officer
Exact text from the filing
Suren Ajjarapu served as Aesther’s Chairman and Chief Executive Officer from Aesther’s inception in June 2021 until the Closing of the Business Combination.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Michael Peterson departed as Board Member at Ocean Biomedical, Inc..
- Role
- Board Member
Exact text from the filing
Michael L. Peterson served on Aesther’s board of directors from September 2021 until the Business Combination.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jack A. Elias was appointed as Class II Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Dr. Jack A. Elias, M.D. 71 Class II Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Peterson was appointed as Class II Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Michael Peterson 60 Class II Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jerome Ringo was appointed as Class I Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
Jerome Ringo (2)(3) 67 Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Suren Ajjarapu was appointed as Class III Director at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
Suren Ajjarapu 52 Class III Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gurinder Kalra was appointed as Chief Financial Officer at Ocean Biomedical, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
Gurinder Kalra, MBA 57 Chief Financial Officer
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Ocean Biomedical, Inc.: Amended and restated bylaws to make changes appropriate for a public operating company, including provisions for special meetings, proxy solicitation, director vacancies, board committees, and stockholder proposals.
- Change
- bylaw amendment
Exact text from the filing
upon the Closing, pursuant to the terms of the Business Combination Agreement, Aesther amended and restated its bylaws to make certain changes that the Board deems appropriate for a public operating company, including, but not limited to, changes to provisions relating to special meetings in lieu of annual meetings, proxy solicitation and voting, director vacancies and removals, Board committees and stockholder proposals.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Ocean Biomedical, Inc.: Amended Certificate filed with the Secretary of State of Delaware, effecting changes to the company's capital stock rights as described in the Proxy Statement.
- Change
- charter amendment
Exact text from the filing
On the Closing Date, Aesther filed its Amended Certificate with the Secretary of State of the State of Delaware.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.7
Ocean Biomedical, Inc.: Company expects the Board to adopt and approve a new Code of Business Conduct and Ethics applicable to all employees, officers, and directors.
- Change
- code of ethics
Exact text from the filing
the Company expects the Board to adopt and approve a new Code of Business Conduct and Ethics applicable to all employees, officers, and directors of the Company.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Ocean Biomedical, Inc.: Company ceased to be a shell company as a result of the Business Combination.
- Change
- shell status
Exact text from the filing
As a result of the Business Combination, the Company ceased to be a shell company as of the Closing.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Ocean Biomedical, Inc. underwent a change of control involving Legacy Ocean for $233,554,320 (closed 2023-02-14).
- Action
- change of control
- Counterparty
- Legacy Ocean
- Consideration
- $233,554,320
- Closing
- 2023-02-14
Exact text from the filing
as of immediately prior to the Closing approximately 23,355,432 shares of the Company’s Class A common stock (with a per-share value of $10.00) with an aggregate value equal to $233,554,320, as adjusted as required by the Business Combination Agreement to take into account net working capital, closing net debt and Legacy Ocean’s transaction expenses, in exchange for
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.